Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 16:04:52 11/02/2026 GMT			5-day change	1st Jan Change
306.70 ^DKK	-2.62%		+0.26%	-6.09%

10:56am	NOVO NORDISK : Deutsche Bank keeps its Buy rating	ZD
09:10am	European companies cut jobs in response to slowing economy	RE

Nykredit Raises Price Target for Novo Nordisk to 440 Danish Kroner (from 400), Reiterates Buy - BN

Published on 01/16/2026 at 11:12 am GMT

Finwire - Translated by Marketscreener - See original

NOVO NORDISK A/S

-2.62%

Nykredit raises its price target for Novo Nordisk to 440 Danish kroner (from 400), reiterates buy - BN

Latest news about Novo Nordisk A/S

10:56am	NOVO NORDISK : Deutsche Bank keeps its Buy rating	ZD
09:10am	European companies cut jobs in response to slowing economy	RE
02-10	Meijer announces new affordable access to GLP-1 medications	RE
02-10	Deutsche Bank Lowers Price Target for Novo Nordisk to 400 Danish Kroner (475), Reiterates Buy	FW
02-10	Global markets live: Alphabet, Instagram, Target, CVS Health, Coca-Cola…
02-10	Retail Hits the Brakes
02-10	Kailera, Hengrui's experimental pill shows 12.1% weight loss in mid-stage trial	RE
02-10	AstraZeneca Reiterates $80 Billion Revenue Goal for 2030 -- Update	DJ
02-10	Novo Nordisk opens new front with patent suit over Hims' Wegovy copies	RE
02-10	Norron Sustainable Equity Down 0.99 Percent in January – Negative Impact from Small Caps	FW
02-10	Novo Nordisk Research Chief Martin Holst Lange Sells Shares for Tax Reasons	FW
02-10	Chinese biotech aims to finish trials by 2028 for spray with Wegovy active ingredient	RE
02-10	NOVO NORDISK : Barclays remains Neutral	ZD
02-10	EMEA Morning Briefing : Stock Futures Trade Mixed; Tech Jitters Ebb	DJ
02-09	Health Care Down on Deal, Lawsuit Activity -- Health Care Roundup	DJ
02-09	Novo Says It's Suing Hims to Halt Obesity Drug Copycats	MT
02-09	Novo Resources Brief: On New Targets at Wyloo Gold, Silver and Antimony Project for Maiden Drill Program	MT
02-09	Dow Hits New High Amid Tech-Led Advance	MT
02-09	Sector Update: Health Care Stocks Fall Late Afternoon	MT
02-09	Novo Nordisk TV Ad for Oral Wegovy Has Misleading Claims, FDA Says	DJ
02-09	Top Midday Decliners	MT
02-09	Equity Markets Mostly Rise Intraday as Tech Jumps	MT
02-09	Top Middle Decliners	MT
02-09	Sector Update: Health Care Stocks Decline Monday Afternoon	MT
02-09	Novo Nordisk's TV Ad for Wegovy Pill Includes 'False or Misleading' Claims, FDA Says	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

03-26 - Annual General Meeting

More about the company